#ImmunityBio has finally crossed the finish line in its marathon bid to get the label for its #bladdercancer therapy, #Anktiva, expanded in the #US.
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#ImmunityBio has finally crossed the finish line in its marathon bid to get the label for its #bladdercancer therapy, #Anktiva, expanded in the #US.
@medchemexpress.bsky.socialThe FDA has expanded the indication for #Anktiva (nogapendekin alfa inbakicept-pmln) + BCG to include adults with BCG-unresponsive non-muscle-invasive bladder cancer with high-grade papillary-only tumors.
🧪Explore Nogapendekin alfa for research use from MedChemExpress: https://ow.ly/r62r50ZXRES
